Document Detail

Single-step maternal serum screening for trisomy 21 in the era of combined or integrated screening.
MedLine Citation:
PMID:  15340255     Owner:  NLM     Status:  MEDLINE    
Single-step maternal serum screening (MSS) in the first (1MSS) or second (2MSS) trimester at maternal age > or =35 years was evaluated in the North Belgian region Flanders, where difficulties are encountered in the general introduction of combined or integrated screening algorithms. The fetal aneuploidy screening database of General Medical Laboratory AML in Antwerp was searched for 2MSS tests between 1992 and 1999 (alpha-fetoprotein, beta-human chorionic gonadotropin (beta-HCG) and unconjugated estriol, cut-off 1:300) and for 1MSS tests between 1999 and 2003 (free beta-HCG and pregnancy-associated plasma protein A, cut-off 1:85). At > or =35 years, the detection rate for trisomy 21 (DR) was 93.8% (15/16) for 2MSS and the screen-positive rate (SPR) was 24.5% (504/2061). For 1MSS, these figures were 85.7% (6/7) and 17.7% (109/615) respectively. To detect one trisomy 21, missed by MSS at > or =35 years of age, an additional number of 1,557 and 506 primary invasive procedures would be needed for 2MMS and 1MSS respectively. We conclude that the performance of both single-step 1MSS and 2MSS at maternal age > or =35 years in Flanders is excellent, even without the combination with ultrasound parameters or integration of first and second trimester parameters. The simplicity of both methods allows to consider them valuable options for fetal aneuploidy screening at advanced maternal age, until high quality combined or integrated screening is accessible to all pregnant women in Belgium.
Wilfried J A Gyselaers; Annie J Vereecken; Erik van Herck; Dany P L Straetmans; Eric T M de Jonge; Willem U A M Ombelet; Jan G Nijhuis
Related Documents :
24025485 - Vitamin b12 metabolism during pregnancy and in embryonic mouse models.
17003555 - Cftr deltaf508 mutation detection from dried blood samples in the first trimester of pr...
8838765 - Unconjugated estriol as maternal serum marker for the detection of down syndrome pregna...
16353275 - The effect of fetal gender on the false-positive rate of down syndrome by maternal seru...
21988675 - Electrophoretic serum protein fraction profile during the different physiological phase...
24464955 - Serum hyperglycosylated human chorionic gonadotrophin at 14-17 weeks of gestation doe...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2004-08-30
Journal Detail:
Title:  Gynecologic and obstetric investigation     Volume:  58     ISSN:  0378-7346     ISO Abbreviation:  Gynecol. Obstet. Invest.     Publication Date:  2004  
Date Detail:
Created Date:  2004-11-16     Completed Date:  2005-04-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7900587     Medline TA:  Gynecol Obstet Invest     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  221-4     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2004 S. Karger AG, Basel.
Department of Obstetrics and Gynaecology, Ziekenhuis Oost Limburg, Schiepse Bos 6, BE-3600 Genk, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Belgium / epidemiology
Down Syndrome / diagnosis*,  epidemiology*
Mass Screening / methods*
Maternal Age
Pregnancy Outcome
Pregnancy Trimester, First / blood
Pregnancy Trimester, Second / blood
Prenatal Diagnosis
Reproducibility of Results

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  T regulatory cells in allergy and health: a question of allergen specificity and balance.
Next Document:  Effect of 12-month therapy with omega-3 polyunsaturated acids on glomerular filtration response to d...